Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Pfizer Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
Prev close 27.53 · gapped above the open, then crossed back over prior close. High/low 27.68 at 6:45 am ET, 27.32 at 9:30 am ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of PFE revenue | Skew |
|---|---|---|---|
| NKTRNektar Therapeutics | 12.00% | 0.01% | 1,133× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Pfizer, related party (1) 2,487 2,487 —”
FILING10-K0001619856-26-000008cik 0001619856disclosed by CRBU
“We have agreed to sell drug substance to Pfizer and Chiesi for the production of Elelyso and Elfabrio, respectively.”
FILING10-K0001104659-26-029858cik 0001006281disclosed by PLX
“Under the terms of the 2025 Pfizer Agreement, we are responsible for conducting the clinical trial for the combined therapies and Pfizer is responsible for supplying atirmociclib to us at no cost.”
FILING10-K0001193125-26-107169cik 0001750284disclosed by OLMA
“In July 2021, we entered into the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound vepdegestrant (ARV-471), or the Licensed Products.”
FILING10-K0001628280-26-011226cik 0001655759disclosed by ARVN
“This increase was partially offset by the non-recurrence of $6.0 million revenue from our licensing agreement with Roche Sequencing Solutions, Inc. ("Roche") entered into in February 2024, and $9.5 million of revenue related to a license agreement with Pfizer Inc. ("Pfizer") entered into in December 2024.”
FILING10-K0001200375-26-000006cik 0001200375disclosed by CDXS
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
$7M relationship1,133× more of NKTR’s book than PFE’s
basisNKTR fy2025 · closed 2025-12 $55MPFE fy2025 · closed 2025-12 $62.6B
“Under the terms of the Pfizer Agreement, we received an upfront payment of $60.0 million.”
FILING10-K0001549595-26-000016cik 0001549595disclosed by NRIX
“During the year ended December 31, 2025 we recognized $12.6 million in collaboration revenue related to our agreement with Pfizer, all of which was recognized upon termination of our agreement with Pfizer in December 2025.”
FILING10-K0001193125-26-126192cik 0001701108disclosed by SPRO
“In January 2020, the Company entered into an exclusive license agreement with Pfizer Inc. ("Pfizer") for Pfizer's clinical and non-clinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which the Company is developing for the treatment of narcolepsy.”
FILING10-K0001193125-26-064267cik 0001579428disclosed by AXSM
“Under the terms of the Pfizer Agreement, Pfizer will supply elranatamab for use in the Phase 1b trial at no cost, while we will sponsor, conduct and pay the costs of the trial.”
FILING10-K0001628280-26-012000cik 0001662579disclosed by CCCC
“In February 2017, we acquired Pfizer Inc.'s ("Pfizer") Hospira Infusion Systems ("HIS") business.”
FILING10-K0000883984-26-000008cik 0000883984disclosed by ICUI
“In December 2025, we entered into an exclusive global license agreement with Pfizer (the "Pfizer License Agreement") to develop, manufacture and commercialize ervogastat, a Phase 2 oral DGAT-2 inhibitor, and two additional early-stage MASH assets.”
FILING10-K0001628280-26-009514cik 0001157601disclosed by MDGL
“Through the Shire License Agreement, we were assigned the rights to the license agreement ("Pfizer Agreement"), with Pfizer Inc. ("Pfizer"), pursuant to which we obtained an exclusive, worldwide license to Pfizer's know-how related to Livmarli, (the "Pfizer Know-How").”
FILING10-K0001759425-26-000013cik 0001759425disclosed by MIRM
“Under the Pfizer Agreement, Pfizer was obligated to transfer to us certain information, records, regulatory filings, materials and inventory controlled by Pfizer and relating to or useful for developing these compounds and to continue to conduct certain ongoing clinical studies until a certain time.”
FILING10-K0001437749-26-005891cik 0001401667disclosed by PBYI
“In December 2020, the Company entered into a license agreement (as amended, the "Pfizer License Agreement") with Pfizer Inc. ("Pfizer") for worldwide development and commercialization rights to ADC product candidates directed to certain licensed targets, including MICVO and PYX-203, and products containing the ADC product candidates.”
FILING10-K0001193125-26-118532cik 0001782223disclosed by PYXS
“Pfizer provided us with an initial quantity of clinical supplies of one of the products for an agreed upon price.”
FILING10-K0001104659-26-023444cik 0001526119disclosed by VSTM
“We previously had development collaborations for azenosertib with Pfizer Inc., GSK plc, and Dana-Farber Cancer Institute.”
FILING10-K0001725160-26-000014cik 0001725160disclosed by ZNTL
“In October 2023, Serina entered into a non-exclusive license agreement with Pfizer to use our POZ polymer technology for use in lipid nanoparticle drug delivery formulations.”
FILING10-K0001708599-26-000016cik 0001708599disclosed by SER
“In April 2018, we acquired certain assets from Pfizer Inc. (Pfizer), including strategic license and collaboration agreements and other intellectual property related to the development and administration of allogeneic CAR T cells for the treatment of cancer.”
FILING10-K0001628280-26-017242cik 0001737287disclosed by ALLO
“In December 2025, we entered into two non-exclusive agreements with Pfizer Inc. ("Pfizer") to leverage proprietary TCR discovery platform and its large‑scale immune receptor–antigen mapping datasets to accelerate therapeutic research in rheumatoid arthritis ("RA") and broader immunology applications.”
FILING10-K0001193125-26-076902cik 0001478320disclosed by ADPT
“In December 2021, we entered into a four-year research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system.”
FILING10-K0001193125-26-065194cik 0001745999disclosed by BEAM
“On January 15, 2026, we entered into a License and Option Agreement with Pfizer Inc. ("Pfizer") for use of our Matrix-M™.”
FILING10-K0001000694-26-000007cik 0001000694disclosed by NVAX
“In December 2014, we entered into a development and commercialization agreement with Pfizer relating to our long-acting hGH-CTP for the treatment of GHD in adults and children (the "Original Pfizer Agreement").”
FILING10-K0001193125-26-076596cik 0000944809disclosed by OPK
“For example, in April 2020 we entered into a research collaboration and license agreement with Pfizer in connection with VLA15, our Lyme disease vaccine candidate. Pursuant to this agreement, Pfizer is leading late-stage development of the vaccine candidate, including conducting the ongoing Phase 3 clinical trials, and, if the Phase 3 data are positive, will have sole control over the timing and nature of its commercialization, which will have a significant impact on Valneva”
FILING20-F0001628280-26-018808cik 0001836564disclosed by VALN
Watchlist prices, news filtered to it, and its next report on your desk.
Pfizer Inc has 14 disclosed suppliers and 21 disclosed customers. Each one is named in an SEC filing, either Pfizer Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
PFE (Pfizer Inc) has 14 disclosed suppliers and 21 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ZNTL −10.43%, in the health bundle.